ECCO 2023

New molecules on the horizon!

A focus on surgery and post-operative maintenance

S1P modulators - a rising class of drugs

Medium-term outcome of IBD patients diagnosed at…

S1P modulators in UC

Prolonged treatment with Ozanimod recaptures remission…

Long-term duration of response with ozanimod in UC

Upadacitinib is efficacious for UC regardless of…

Long-term extension of ustekinumab in UC

Upadacitinib for fistulizing Crohn´s disease?

Latest update on JAK inhibition

Mucosal healing induced by vedolizumab in chronic…

Upadacitinib works in bionaive and bio-exposed pts in…

No impact of previous therapies for Upadacitinib in…

Update zu JAK-Inhibitoren bei CED

Upadacitinib: Vortherapien spielen keine Rolle mehr bei…

Lang Termijn respons met ozanimod bij colitis ulcerosa

Upadacitinib is efficient bij colitis ulcerosa,…

Il prolungamento del trattamento con Ozanimod induce…

Η μεσοπρόθεσμη έκβαση ασθενών με ΙΦΝΕ που…

S1P-Modulatoren bei Colitis ulcerosa

Anti-IL23 drugs: is it all the same?

Safety update on JAKis - new worries?

New aspects on safety of anti-TNF treatment

Ileostomy with better prognosis than pouch in PSC

Risk of IBD from early antibiotic exposure in live

Ozanimod shows good efficacy and safety profile in UC…

Etrasimod shows fast stool frequency and rectal…

Ileostomie mit besserer Prognose als Pouch bei PSC

Rapido controllo del sanguinamento rettale e della…

Les antibiotiques dans la petite enfance augmentent le…

Ozanimod shows good efficacy and safety profile after…

10 years of Tofacitinib – still more lessons to learn

DNA methylation predicts response to biologics in IBD

Biologics in CD – is earlier better?

Timing of surgery in Crohn's disease

Another clue for the role of the microbiome in PSC?

Surgical and post-operative management in CD

Enteral nutrition - food for thought!

Epigenetic fingerprinting - a novel tool for precision…

Surgery in CD - resetting or not?

Vedolizumab for preventing postoperative reccurence of…

Post-surgical Crohn's disease

Early treatment with biologics in IBD

Vedolizumab prevents postoperative recurrence in CD

Is it feasible to stop anti-TNF treatment in…

Peri- and postoperative management of CD

Ileocaecal Crohn's disease - should we call the surgeon…

New drugs on the block!

Biologics in CD - is earlier better?

Epigenetic Fingerprinting - ein neues Werkzeug für die…

Aanpak van de (post)operatieve Crohn patient

Vedolizumab previene la recidiva post operatoria nei…

Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες…

Neue Substanzen!

Chirurgischer Verlauf nach Morbus Crohn

Postać ileocekalna choroby Crohna - czy chirurgia ma…

Résection chirurgicale au course de la maladie de…

Another clue for the role of the microbiome in PSC?

Vedolizumab en prévention de la récidive postopératoire…

Peri- und postoperatives Management bei Morbus Crohn

Résection chirurgicale précoce dans la MC

Comprehensive remission - the new standard!?

Comprehensive Disease Control

New opportunities from the application of artificial…

Comprehensive overview of surgery in IBD

GPX4 fueling postoperative recurrence in Crohn's…

Mucosal signatures suggest a mechanism for early CD…

Sequencing in IBD - congress overview

Our patients will be better off in the near future!

Panoramica completa sulla chirurgia nelle malattie…

GPX4 fördert postoperatives Morbus Crohn Rezidiv

Una vida mejor en el futuro inmediato para nuestros…

Sequencing nelle malattie infiammatorie cronicale…

Nowe wytyczne ECCO dotyczące manifestacji…

Nuove opportunità dall’applicazione dell’intelligenza…